PRINCETON, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Duke Translational Medicine Institute (DTMI) today announced the formation of a strategic relationship to ...
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...
A company that specialises in turning university research into marketable drugs is licensing Harvard research related to the blue evergreen hydrangea root, a part of the plant that has been used in ...
Professor Davey Smith's contributions to medical research have marked him as among the most highly recognised scientists ...
Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies “We are ...
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, ...
Thousands of NHS knee replacement operations are canceled at short notice every year, many for avoidable reasons, according ...
Prime Medicine (NASDAQ:PRME) and Bristol Myers Squibb (NYSE:BMY) will work together on the development of next-generation ex vivo T-cell therapies. The deal calls for Prime Medicine to design ...
“It’s never too late” – these are the words Paul Edwards stands by, as he achieves his dream of graduating as a doctor from the University of Bristol. It's a milestone that almost never came as Paul’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback